Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q2 2015 · 10-Q
Revenue$184.40M$184.40M−9.6% vs Q2 2014 Net Income$24.00M$24.00M−52.3% vs Q2 2014 EPS Diluted$0.32$0.32−51.5% vs Q2 2014 Operating Income$36,300,000−56.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$46,600,000+4.2% Margins · derivedOperating margin19.7%−21.0 pt vs Q2 2014
Net margin13.0%−11.7 pt vs Q2 2014
ended Dec 31, 2014 · filed Feb 4, 2015 · 35 d after period end